Additionally, one trial compared the efficacy of PD-1 inhibitors plus chemotherapy against a combination of PD-1 inhibitors and CTLA-4 inhibitors in immunotherapy for ESCC. This evidence concerns the gene CTLA4 and esophageal squamous cell carcinoma.